Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
Alyna Turner, John J McGrath, Olivia M Dean, Seetal Dodd, Andrea Baker, Susan M Cotton, James G Scott, Bianca E Kavanagh, Melanie M Ashton, Adam J Walker, Ellie Brown, Michael Berk
Clinical Psychopharmacology and Neuroscience | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | Published : 2019
Awarded by John Cade Fellowship from the National Health and Medical Research Council
Awarded by NHMRC
Awarded by NHMRC Senior Research Fellowship
Awarded by National Health and Medical Research Council Practitioner Fellowship Grant
This study is being funded by the Stanley Medical Research Institute. All authors gratefully acknowledge their support.Alyna Turner has received travel or grant support from the National Stroke Foundation, Hunter Medical Research Institute, Helen Macpherson Smith Trust, Schizophrenia Fellowship NSW, SMHR, ISAD, and the University of Newcastle. John J. McGrath is supported by grant APP1056929 from the John Cade Fellowship from the National Health and Medical Research Council. Olivia M. Dean is a R.D. Wright Biomedical Research Fellow and has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. Olivia M. Dean gratefully acknowledges the support of the NHMRC (APP1145634). Seetal Dodd has received grant support from Stanley Medical Research Institute, NHMRC, Beyond Blue, ARHRF, Simons Foundation, Geelong Medical Research Foundation, Fondation FondaMental, Eli Lilly, Glaxo SmithKline, Organon, Mayne Pharma and Servier. He has received speaker's fees from Eli Lilly, advisory board fees from Eli Lilly and Novartis and conference travel support from Servier. Andrea Baker reports no disclosures. Susan M. Cotton has received grant support from the NHMRC, the Stanley Medical Research Institute, BeyondBlue, Movember, The University of Melbourne, Australian Catholic University, ARHRF, and Mental Illness Research Fund (Victoria Department of Human Services). She is supported by a NHMRC Senior Research Fellowship (APP1136344). James G. Scott is supported by a National Health and Medical Research Council Practitioner Fellowship Grant (APP1105807), has been a speaker for Janssen Cilag, Lundbeck, Servier, and Shire Pharmaceuticals, and served as a consultant to Janssen Cilag, Lundbeck and Roche. Bianca E. Kavanagh has received research support from the Australian Government Research Training Program Scholarship, and Ian Scott Mental Health PhD Scholarship, Australian Rotary Health. Melanie M. Ashton has received grant/research support from Deakin University, Australasian Society for Bipolar Depressive Disorders, Lundbeck, Australian Rotary Health, Ian Parker Bipolar Research Fund, Cooperative Research Centre for Mental Health and PDG Geoff and Betty Betts Award from Rotary Club of Geelong. Adam J. Walker was previously supported by an Australian Postgraduate Award and an HDR Writing Award from Deakin University. Ellie Brown has received travel and grant support from the University of the West of England, UK. Michael Berk has received grant support from NIH, Simons Autism Foundation, Cancer Council of Victoria, CRC for Mental Health, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier. Michael Berk has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier. Michael Berk is a co-inventor on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, assigned to the Mental Health Research Institute.